Barbara Galaini - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Role
Principal Accounting Officer and Controller
Signature
By: /s/ Richard Cunningham as attorney-in-fact for Barbara Galaini
Issuer symbol
N/A
Transactions as of
16 Sep 2022
Net transactions value
$0
Form type
4
Filing time
16 Sep 2022, 18:00:41 UTC
Previous filing
26 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYME Common Stock Disposed to Issuer -258,300 -100% 0 16 Sep 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -200,000 -100% 0 16 Sep 2022 Common Stock 200,000 $2.25 Direct F2
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -50,000 -100% 0 16 Sep 2022 Common Stock 50,000 $2.25 Direct F3
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -179,700 -100% 0 16 Sep 2022 Common Stock 179,700 $1.56 Direct F4
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -225,000 -100% 0 16 Sep 2022 Common Stock 225,000 $1.39 Direct F5
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -280,000 -100% 0 16 Sep 2022 Common Stock 280,000 $1.43 Direct F6
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -258,300 -100% 0 16 Sep 2022 Common Stock 258,300 $0.3200 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Barbara Galaini is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 11,318 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
F2 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 8,764 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.
F3 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.
F4 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 7,874 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
F5 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 9,859 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
F6 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 12,269 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
F7 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,318 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.

Remarks:

Principal Accounting Officer and Controller